LH Stock Analysis — LabCorp
Sector: Healthcare
AI Verdict
LabCorp trades at 14.8x next year's earnings while analysts expect +70.7% EPS growth—this is cheap for the growth on offer, and the scale moat in diagnostics makes those expectations more credible than most.
Competitive Moat
LabCorp operates one of the largest diagnostic laboratory networks in the U.S., creating scale advantages in test processing, logistics, and payer negotiations. Its entrenched relationships with hospitals and insurers make it difficult for new entrants to compete on both cost and reach.
Summary
LabCorp is notable for a forecasted 70.7% jump in earnings per share over the next year, paired with a forward P/E of just 14.8x.
Where It Stands
The stock returned 15.54% over the past year, trades at 14.8x forward earnings versus a healthcare median of 22x, and its RSI of 44.6 signals cooling momentum rather than overbought risk.
Key Metrics
- RSI: 44.6 — Neutral
- Trailing P/E: 25.2x
- Forward P/E: 14.8x
- PEG Ratio: 0.36
- Earnings Growth: +0.7%
- Revenue Growth: +0.1%
- Market Cap: $21.7B
- Dividend Yield: 0.01%
- 1-Year Return: 15.54%
- 52-Week High: $293.72
- 52-Week Low: $218.76
Analyst Consensus
23 Buy · 6 Hold · 0 Sell (29 analysts)
Bull Case
With analysts expecting 70.7% EPS growth and a forward P/E of 14.8x, you're getting rapid earnings growth at a price below the sector average.
Bear Case
If the P/E reverted to the sector median of 22x, the stock could see a sharp rerating if growth disappoints or if the 44.6 RSI drops further into oversold territory.
Catalyst to Watch
Watch for upcoming quarterly results—if earnings growth matches the 70.7% consensus, it could trigger a valuation re-rate.